Based on recent data, Bright Minds Biosciences Inc. (DRUG) shows an Average True Range (ATR) of 6 and an Enterprise Value of -176.18K. Its average trading volume over the past 3 months is 276.97K, indicating liquidity. These fundamental metrics provide insight into DRUG's underlying financial health and market activity.
| ATR | 6 |
| Enterprise Value | -176.18K |
| Avg Vol (3 Months) | 276.97K |
| Avg Vol (10 Days) | 236.97K |
Bright Minds Biosciences Inc. (DRUG) technical indicators as of June 23, 2026: the SMA 20 is 6.01%, SMA 50 at 2.19%, and SMA 200 at 56.62%. The RSI 14 value is 53.78, suggesting its current momentum. These technical analysis signals help assess DRUG's price trends and potential future movements.
| SMA 20 | 6.01% |
| SMA 50 | 2.19% |
| SMA 200 | 56.62% |
| RSI 14 | 53.78 |
Bright Minds Biosciences Inc. (DRUG) stock performance overview as of June 23, 2026: The 52-week high is $123.75 (currently -30.91% below), and the 52-week low is $23.18 (currently 268.93% above). Over the past year, DRUG's performance is 126.78%, compared to the S&P 500's 10.67% change.
| 52-Week High | 123.75 |
| 52-Week High Chg | -30.91% |
| 52-Week Low | 23.18 |
| 52-Week Low Chg | +268.93% |
| S&P 500 52-Week Chg | 10.67% |
According to market data, Bright Minds Biosciences Inc. (DRUG) stock's recent performance metrics show that over the last month, DRUG is -5.77%, with a Year-to-Date (YTD) performance of 6.36%. Over the past year, the stock has seen a 126.78% change. These figures summarize DRUG's price movements across various periods, reflecting its historical returns.
| Period | 1 Week | 1 Month | Quarter | Half Year | 1 Year | YTD |
|---|---|---|---|---|---|---|
| High | 63.81 | 92 | 92.39 | 123.75 | 123.75 | 123.75 |
| Low | 56.47 | 56.47 | 56.47 | 56.47 | 23.18 | 56.47 |
| Performance | -6.39% | -5.77% | +31.45% | +217.52% | +126.78% | +6.36% |
According to current financial data, DRUG stock's P/E (TTM) ratio is -27.17, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.22. Key valuation ratios for DRUG, including P/S (N/A), P/B (2.74), and P/FCF (-34.02), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.
| Valuation | DRUG | Sector Median | Industry Avg | S&P 500 |
|---|---|---|---|---|
| P/E (TTM) | -27.17 | -1.22 | -5.02 | 32.59 |
| P/S (TTM) | N/A | 3.69 | 462.04 | 5.98 |
| P/B (TTM) | 2.74 | 1.23 | 12.18 | 5 |
| P/FCF (TTM) | -34.02 | -11.37 | -908.56 | 28.32 |
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep